{"anticipatedPostingDate":"2027-06","denomUnitsSelected":"Participants","description":"To determine the efficacy of durvalumab in combination with platinum-based chemotherapy (paclitaxel and carboplatin) followed by maintenance durvalumab or durvalumab with olaparib when compared to platinum-based chemotherapy in newly diagnosed advanced or recurrent endometrial cancer patients by assessment of TDT","reportingStatus":"NOT_POSTED","timeFrame":"Time elapsed from randomisation to study treatment discontinuation or death. Assessed through study completion, up to 83 months","title":"Time From Randomisation to Discontinuation of Treatment or Death (TDT)","type":"SECONDARY"}